Akums Drugs and Pharmaceuticals has reported results for first quarter ended June 30, 2026 (Q1FY27).
The company has reported marginal fall by 0.07% in its net profit at Rs 44.84 crore for the quarter ended June 30, 2026 as compared to Rs 44.87 crore for the same quarter in the previous year. However, total income of the company has increased by 15.90% at Rs 418.38 crore for Q1FY27 as compared to Rs 361.00 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 57.55% jump in its net profit at Rs 100.01 crore for Q1FY27 as compared to Rs 63.48 crore for the same quarter in the previous year. The total income of the company has increased by 13.92% at Rs 1,197.01 crore for Q1FY27 as compared to Rs 1,050.76 crore for the corresponding quarter previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1936.20 |
| Dr. Reddys Labs. | 1192.05 |
| Cipla | 1459.35 |
| Lupin | 2267.60 |
| Zydus Lifesciences | 1159.70 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: